| 查看: 487 | 回复: 2 | ||
[求助]
求助-汤森路透药物报告 已有1人参与
|
|
求助Arbidol的汤森路透药物报告，谢谢！ [ Last edited by 审雨堂88 on 2014-2-27 at 09:55 ] |
回复此楼» 猜你喜欢
求26届aidd博导推荐
已经有4人回复
-
2026申博推荐
已经有1人回复
-
药物学论文润色/翻译怎么收费?
已经有203人回复
-
一篇扩散模型的Nature Machine Intelligence论文和Elsevier上的深度学习药物书籍
已经有1人回复
-
中国药科大学2026入学博士，药物合成和设计经验，放射化学及放射医学研究
已经有25人回复
-
使用MolAICal进行多肽虚拟筛选教程-同样适用于蛋白质和核酸的虚拟筛选
已经有1人回复
-
使用MolAICal计算药物化学过滤器MCFs及MCE-18描述符
已经有0人回复
-
使用MolAICal发现蛋白受体潜在的活性口袋及位点
已经有0人回复
» 本主题相关价值贴推荐，对您同样有帮助:
- 汤姆森数据库求助
已经有7人回复
- 求助一个汤姆森报告
已经有3人回复
- 求助索利那新（solifenacin）和帕立骨化醇（paricalcitol） 的汤森路透报告
已经有8人回复
- 汤森路透2014需要重点关注的药物
已经有449人回复
- 汤森路透-药物化学在研发角色的转变（2013年6月7日 ）【已搜索无重复】
已经有164人回复
- 求：2013版的抗高血压药物市场研究报告~
已经有5人回复
- 临床前研究指南（CFDA和FDA，新的和旧的，共四个）
已经有206人回复
- 求助汤森路透药物研究报告
已经有4人回复
- 求助关于药物对照品的问题
已经有18人回复
- 糖尿病药物市场调查报告 2012
已经有135人回复
- 降血脂药物市场研究报告（2012年版）
已经有411人回复
- 【求助】缓释制剂临床试验
已经有11人回复
- 【求助】请问医药信息调研报告包括哪些方面的内容？
已经有20人回复
- 【求助】有关中药资源调查报告的问题
已经有5人回复
- 【求助】求助一篇调查报告
已经有9人回复
- 【求助】##药物生产工艺技术可行性报告怎么写
已经有5人回复
- 【求助】想学计算机辅助药物设计
已经有28人回复
【答案】应助回帖
★ ★ ★ ★ ★
感谢参与，应助指数 +1
审雨堂88: 金币+5, ★有帮助, 谢谢 2014-02-27 16:02:09
感谢参与，应助指数 +1
审雨堂88: 金币+5, ★有帮助, 谢谢 2014-02-27 16:02:09
|
Accession No: 18965 Main Details Drug Name World Status Pharma Status Arbidol Launched Fully Launched Latest Change Updated On By Latest Change 3 Jun 1994 UN Minor change Company Status Data Originator Country Development Stage Non-industrial source Unspecified Launched Activity Data Therapy Description Code Therapy Status Immunostimulant, other I1Z Launched Antiviral, other J5Z Launched Pharmacology Description Code Immunostimulant IM+ Therapy Code Pharmacology Code I1Z J5Z IM+ IM+ Route of Administration Route of Administration Code Alimentary, po A-PO Indication Indication Status Infection, influenza virus Launched Target Data Target Name LocusLink/Entrez Gene ID Unspecified Unspecified -------------------------------------------------------------------------------- Target Family Group(s) Receptor > Cytokine receptor > Class II Chemical Data Origin of Material Code Description CH-SY Chemical, synthetic CAS Registry Number Rotatable Bonds Molecular Formula 131707-23-8 9 C22H26BrClN2O3S Hydrogen Bond Acceptors Hydrogen Bond Donors AlogP Molecular Weight 6 1 4.50 477.42 Chemical Name 1H-indole-3-carboxylic acid, 6-bromo-4-((dimethylamino)methyl)-5-hydroxy-1-methyl-2-((phenylthio)methyl)-, ethylester, monohydrochloride [CAS] Structure New Chemical Entity Yes Patent Data Country Number Priority Country Priority Date WO 9008135 WO 12 January 1989 Country Data Country Name Country Status Year Launched Licensing Op. Argentina - Yes Australia - Yes Austria - Yes Belgium - Yes Brazil - Yes Canada - Yes Chile - Yes China - Yes Colombia - Yes Denmark - Yes Finland - Yes France - Yes Germany - Yes Greece - Yes Hong Kong - Yes India - Yes Ireland - Yes Israel - Yes Italy - Yes Japan - Yes Luxembourg - Yes Malaysia - Yes Mexico - Yes Netherlands - Yes New Zealand - Yes Norway - Yes Peru - Yes Philippines - Yes Portugal - Yes Russian Federation Launched Yes South Africa - Yes South Korea - Yes Spain - Yes Sweden - Yes Switzerland - Yes Thailand - Yes Turkey - Yes UK - Yes USA - Yes Venezuela - Yes Major Events Event Date Act/Est Event Details 15 Oct 1992 Est New Product in Pharmaprojects 15 Oct 1992 Est Licensing Opportunities Worldwide Ratings Novelty Market Size Speed Total Established Strategy (2) US$ 0-500 million (1) Not available (0) Not available Detailed Information Arbidol is an interferon-inducer, developed by Dr I S Nikolaeva of the Centre for Chemistry of Drugs, VNIKhFI, Zubovskay Street 7, Moscow 119517, Russia, as a therapeutic and prophylactic for influenza A and B and other respiratory viral infections (Personal communication, Sep 1992). Marketing It is launched in Russia for therapeutic use in influenza A and B. Clinical Phase III In 2000 influenza patients, Arbidol 0.2g po tid or qid for 3 days reduced the duration of fever, catarrhal syndrome and overall disease, and prevented the development of post-influenzal complications. A prophylactic effect was achieved by 100mg twice/wk. It had an efficacy index of 5.16 (cf 1.0 for ramantadine) (18th Int Cong Chemother (Stockholm), 1993, Abs 190; Personal communication, Jun 1993). In 12 volunteers, 300mg/kg po produced interferon titres of 160IU/ml 24hr after administration (4th BICON (Prague), 1992, Abs 155). Preclinical In cell culture, it inhibited the plaque-forming activity of influenza virus without affecting its haemagglutinating activity. Licensing Arbidol is available for licensing worldwide (Personal communication, Sep 1992). |
2楼2014-02-27 10:17:11
3楼2014-02-27 10:41:51